Mycobacterium abscessus Infection of a Puncture Wound of the Hand
| | | |
The authors present a case report of a patient who suffered
a puncture wound of the hand. The patient developed a chronic wound
on the dorsum of her hand secondary to Mycobacterium abscessus.
Debridement of the wound was performed and operative cultures grew
M abscessus. Treatment of cutaneous infections from this organism
includes debridement, culture of the organism, appropriate antibiotics,
and wound care.
An elderly patient with a traumatic, nonhealing wound underwent surgical debridement of the affected area. Operative cultures grew Mycobacterium species. Case Report A 90-year-old woman suffered a puncture wound to the dorsum on her left hand while using scissors that she owned for the past 70 years. Her primary care physician initially treated the wound with povidone-iodine soaks and Xeroform™ gauze dressings (Tyco Healthcare/Kendall, Mansfield, Mass). Her wound failed to heal with this regimen, and she was referred for evaluation and treatment of her wound approximately 60 days post injury (Figure 1).
Figures 1 and 2.
|  | |
Her past medical history was significant for peptic ulcer disease, angina, osteoporosis, osteoarthritis, hypothyroidism, hypertension, and anemia. On examination, this frail, elderly woman was afebrile and in no acute distress. She had no palpable lymphadenopathy and her sclera were clear. There were no intraoral lesions and her lungs were clear. Her abdomen was soft, flat, non-tender and no masses were visible or organomegaly palpable. There was no guarding, rebound or rigidity. There was a 7-mm x 5-mm open wound of the dorsum of the left hand, with induration, edema, slight erythema, and was tender to the touch. There was no increased warmth, necrosis, exudate, or maceration. Some gray discharge was evident. The patient underwent an excisional debridement in the operating room on an elective basis. The subcutaneous tissue was noted to be brownish in color when it was debrided. A tissue sample was submitted to the North Shore-Long Island Jewish Health System Laboratories (Lake Success, NY). The sample was processed according to standard laboratory procedures for the detection of Mycobacterium spp. The tissue sample was ground, decontaminated, and digested using an N-acetyl-L-cysteine (NALC) procedure(Alpha-Tec Systems Inc,Vancouver,Wash). The processed sample was used to inoculate a MIGT tube incubated at 37°C, Lowenstein-Jensen (LJ) agar slants (37°C and 30°C), and a chocolate agar slant (30°C). Fluorochrome stained smear of the processed sample was negative. The initial cultures grew Staphylococcus aureus. Growth was detected on day 13 in the MGIT tube, and LJ media incubated at 25°C and 30°C. Subcultures grew within 7 days at 25°C, 30°C, and 37°C. DNA probes of M tuberculosis and M avium-intracellulare complex were negative. Standard biochemical tests used to identify mycobacteria and growth on MacConkey agar suggested the organism belonged to the Mycobacterium chelonae/abscessus group. Final identification of the organism was performed at the National Jewish Medical and Research Center (Denver, Colo). The isolate was subsequently identified as Mycobacterium abscessus. The patient was admitted to the hospital and was started on cefoxitin and amikacin intravenously (IV) after a consultation with the infectious disease specialist. The isolate was eventually reported to be susceptible to amikacin, kanamycin, tobramycin, tigecycline, clarithromycin, and azithromycin, with intermediate sensitivity to imipenem, ciprofloxacin, linezolid, and resistant to cefoxitin, doxycycline, and gatifloxacin, moxifloxacin, amoxicillin/clavulanate potassium, and trimethoprim/sulfamethoxazole. The patient received 6 days of in-patient IV antibiotic therapy with amikacin and cefoxitin. She was discharged from the hospital on clarithromycin 500 mg po BID. She was seen in the author’s office weekly and was referred to the Visiting Nurse Service of Long Island for home care. Treatment regimen consisted of washing the wound with a wound cleanser and rinsing with normal saline. SilvaSorb Gel™ (Medline, Mundelein, Ill) was applied topically to the wound and was covered by a dry sterile dressing. Dressing changes were performed 3 times a week—Monday, Wednesday, and Friday. The patient resided in a senior citizen complex. Several weeks after discharge, she tripped while using her walker, fell, and struck her head. She was transported via ambulance to a different hospital where she had been previously treated. A CT scan of the brain revealed an acute right subdural hematoma. The patient underwent an evacuation of the hematoma. She made an uneventful recovery, and was discharged home. During this admission, an IV was started near the infected site on her left hand. While at home, visiting nursing service was reinstituted using the same wound care protocol. Within a week, the patient developed mental status changes and required readmission to the hospital.A CT scan revealed a left subdural hematoma. This hematoma was also evacuated. On this admission, an IV was also started in the affected hand near the wound site. The patient recovered and was again discharged to home. During the 6 months after starting treatment on clarithromycin, and 3 times weekly dressing changes, the wound slowly improved. After the initial course of therapy, it was noted that there was persistent edema and induration around the wound. The wound closed after 180 days of therapy (Figure 2). The patient continued to complain of pain and tenderness in the area. She continued on clarithromycin because of persistent complaints of pain and physical findings of edema and mild erythema. A dressing was applied to the hand as a protectivemeasure. On 1-month follow-up the wound was found to be open. The area surrounding the wound was palpated, and a small amount of purulent material was drained. The previous wound care regimen was resumed and the wound closed again in about 2 weeks. The patient completed a 9-month course of oral clarithromycin, after which the wound has remained closed. There was no induration, edema, tenderness, or erythema when antibiotic therapy and wound care were completed.
Discussion Moore and Frerichs1 recovered a rapidly growing mycobacterium (RGM) from a knee abscess in 1953 that was identified as a new species, Mycobacterium abscessus. M abscessus is an acid-fast rod classified as pathogenic nontuberculous mycobacteria, formerly classified as M chelonae subspecies abscessus. Although these organisms are ubiquitous in the environment and have been found in municipal and well water, soil, and dust, they rarely cause disease.2 The species of RGM capable of producing disease in humans consist primarily of the M fortuitum group, the M chelonae/abscessus group, and the M smegmatis group.3 Human infections caused by these organisms have been reported in most areas of the world.4 Species of RGM have been recovered from 30% to 78% of soil samples throughout the United States.5 Outbreaks can involve exposure to tap water or water sources, such as ice and water-based solutions.6 M abscessus infections have been recognized in patients with cystic fibrosis,7 with implantable devices,8 after cosmetic surgery,9–12 after eye surgery,13 in hemodialysis patients,14 after cardiac surgery,15 as a cause of osteomyelitis,16 after injections,17–19 as a cause of peritoneal catheter associated infections,20 in tsunami survivors,21 and in animals.22 Bacteremia and disseminated infections, although rare, occur most commonly in immunocompromised hosts.23,24 Diagnosis and Treatment Clinical disease can be recognized when a wound fails to heal or when a previously healed wound recurs, as seen in the presented case. Frequently the disease begins as a localized abscess and cellulitis that progresses to multiple, recurrent skin abscesses and fluctuant nodules. The wounds are often tender and have mild surrounding erythema. Chronic ulcerative lesions can develop, which might have extensive subcutaneous necrosis. The extent of the necrosis is often not appreciated until the wound is debrided. The lesions can be multiple and are frequently surrounded by indurated tissue.25,26 Diagnosis of infection relies on culture and identification of the organism. Rapidly growing mycobacterium grow in common laboratory broth (eg, tryptic soy broth) in 5–8 days without supplementation.2 Treatment involves excision, debridement, and curettage of all infected tissue, and excision of foreign bodies and infected implanted devices, as well as antimicrobial therapy.27–29 Pneumonectomy, lobectomy, or wedge resection, may be required for pulmonary disease.30 Rapidly growing mycobacterium are resistant to antituberculous agents, but are susceptible to a number of traditional antibacterial agents.20 Isolates of M abscessus are susceptible to clarithromycin (100%), clofazimine (90%), amikacin (90%), cefoxitin (70%), and imipenem (50%).31,32 No controlled clinical trials of treatment for M abscessus comparing one form of treatment with another have been performed; however, guidelines have been suggested for drug therapy on nonpulmonary disease caused by RMG.33 The only clinical trial on M chelonae skin disease was done with clarithromycin. Of patients (all adults) treated with monotherapy at 500 mg twice a day for 6 months, all were cured except one patient who relapsed with an isolate that developed resistance to clarithromycin.34 Azithromycin also appears to work well, but there is less clinical experience with this agent.2 Serious, extensive, or disseminated infection requires intravenous therapy initially.18 Generally, treatment should continue for 4 to 6 months for skin, soft tissue, and bone infections. Conclusion Nonhealing wounds should be biopsied and cultured. Tissue should be cultured for aerobic, anaerobic, and Mycobacterium species. Prolonged treatment for Mycobacterium infection is common. Acknowledgment The authors give special thanks to the Visiting Nurse Association of Long Island and to Elizabeth Brown, RN for the care of this patient. Special thanks to Nancy Caporasa of the North Shore-Long Island Jewish Health Systems Microbiology Laboratory for her assistance with organism identification and explanation of the process used in identifying the organism. |
References 1. Moore M,Frerichs JB.An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of thegluteal region: report of a case with a study of the organism, Mycobacterium abscessus, n.sp. J Invest Dermatol. 1953;20(2):133–169. 2. Centers for Disease Control and Prevention (CDC). Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract— Colorado and Wyoming, 1995–1996. MMWR. 1996;45(33):713–715. 3. Brown-Elliott BA,Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15(4):716–746. 4. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979;119(1):107–159. 5. O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey.Am Rev Respir Dis. 1987;135(5):1007–1014. 6. Jarvis WR.Nosocomial outbreaks: the Centers for Disease Control’s Hospital Infections Program experience, 1980–1990. Epidemiology Branch, Hospital Infections Program. Am J Med. 1991;91(Suppl 3B):101S–106S. 7. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis: colonization or infection? Am J Respir Crit Care Med. 2000;161(2 Pt 1):641–645. 8. Cutay AM, Horowitz HW, Pooley RW, Van Horn K, Wormser GP. Infection of epicardial pacemaker wires due to Mycobacterium abscessus. Clin Infect Dis. 1998;26(2):520–521. 9. Centers for Disease Control and Prevention (CDC). Brief Report: Nontuberculous mycobacterial infections after cosmetic surgery—Santo Domingo,Dominican Republic, 2003–2004.MMWR. 2004;53(23):509. 10. Centers for Disease Control and Prevention (CDC). Mycobacterium chelonae infections associated with face lifts—New Jersey, 2002–2003. MMWR. 2004;53(09):192–194. 11. Centers for Disease Control and Prevention (CDC). Rapidly growing mycobacterial infection following liposuction and liposculpture—Caracas, Venezuela, 1996–1998.MMWR. 1998;47(49):1065–1067. 12. Newman MI, Camberos AE, Ascherman J. Mycobacteria abscessus outbreak in US patients linked to offshore surgicenter. Ann Plast Surg. 2005;55(1):107–110. 13. Centers for Disease Control and Prevention (CDC). Epidemiologic notes and reports mycobacterium chelonae infections following eye surgery—Texas. MMWR. 1983;32:591–598. 14. Centers for Disease Control and Prevention (CDC). Epidemiologic notes and reports nontuberculous mycobacterial infections in hemodialysis patients— Louisiana, 1982.MMWR. 1983;32(18):244–246. 15. Samuels LE, Sharma S,Morris RJ, et al.Mycobacterium fortuitum infection of the sternum. Review of the literature and case illustration. Arch Surg. 1996;131(12):1344–1346. 16. Maxson S, Schutze GE, Jacobs RF. Mycobacterium abscessus osteomyelitis: treatment with clarithromycin. Infect Dis Clin Pract. 1994;3:203–204. 17. Meredith FT, Sexton DJ. Mycobacterium abscessus osteomyelitis following a plantar puncture wound. Clin Infect Dis. 1996;23(3):651–653. 18. Cluster of Mycobacterium abscessus infections following injections for cosmetic purposes, 2005. Available at: http://www.nyc.gov/html/doh/downloads/pdf/cd/06md 01.pdf.Accessed: November 13, 2007. 19. Zhibang Y, Bixia Z, Qishan L, Lihao C, Xiangquan L, Huaping L. Large-scale outbreak of infection with Mycobacterium chelonae subspecies abscessus after penicillin injection. J Clin Microbiol. 2002;40(7):2626–2628. 20. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis. 1992;166(2):405–412. 21. Petrini B, Farnebo F, Hedblad MA, Appelgren P. Concomitant late soft tissue infections by Cladophialophora bantiana and Mycobacterium abscessus following tsunami injuries. Med Mycol. 2006;44(2):189–192. 22. Raymond JT, Tell L, Bush M, Nichols DK, Schulman FY, Montali RJ. Subcutaneous atypical mycobacteriosis in captive tiger quolls (Dasyurus maculatus). Vet Pathol. 2000;37(2):137–142. 23. Ingram CW, Tanner DC, Durack DT, Kernodle GW Jr, Corey GR. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis. 1993;16(4):463–471. 24. Horsburgh CR Jr, Selik RM.The epidemiology of disseminated nontuberculous mycobacterial infection in acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis. 1989;139(1):4–7. 25. Fenske NA, Millns JL. Resistant cutaneous infection caused by Mycobacterium chelonae. Arch Dermatol. 1981;117(3):151–153. 26. Franck N, Cabie A,Villette B,Amor B, Lessana-LeibowitchM, Escande JP. Treatment of mycobacteria chelonaeinduced skin infection with clarithromycin. J Am Acad Dermatol. 1993;28(6):1019–1021. 27. Prinz BM, Michaelis S, Kettelhack N, Mueller B, Burg G, Kempf W. Subcutaneous infection with Mycobacterium abscessus in a renal transplant recipient. Dermatology. 2004;208(3):259–261. 28. Plaus WJ,Hermann G.The surgical management of superficial infections caused by atypical mycobacteria. Surgery. 1991;110(1):99–103. 29. Rappaport W, Dunington G, Norton L, Ladin D, Peterson E, Ballard J. The surgical management of atypical mycobacterial soft tissue infections. Surgery. 1990;108(1):36–39. 30. Shiraishi Y, Nakajima Y, Katsuragi N,Kurai M,Takahashi N. Pneumonectomy for nontuberculous mycobacterial infections. Ann Thorac Surg. 2004;78(2):399–403. 31. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. The official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.Am J Respir Crit Care Med.1997;156(2 Pt 2):S1–S25. 32. Centers for Disease Control and Prevention. Analyses of January 2007 M tuberculosis and Nontuberculous Mycobacteria Drug Susceptibility Test Results Reported by Participating Laboratories. Available at: http://wwwn.cdc.gov/mpep/pdf/mtb/TBNTM200701.p df.Accessed November 14, 2007. 33. Wallace RJ Jr. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria M. fortuitum and M. chelonae. Clin Chest Med. 1989;10(3):419–429. 34. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to mycobacterium chelonae. Ann Intern Med. 1993;119(6):482–486. |
| Wounds - ISSN: 1044-7946 - Volume 19 - Issue 12 - December 2007 - Pages: 345 - 349 | |
|
|